Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Amlodipine Krka 10 mg Tablets
Medicines register · Ireland

Amlodipine Krka 10 mg Tablets

Authorisation PA1347/034/002 · KRKA, d.d., Novo mesto

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
KRKA, d.d., Novo mesto (all products →)
Active substance
Amlodipine
Clinical trials
10 clinical trials →
Dosage form
Tablet
Route of administration
Oral use
ATC codes
C08CA, C08CA01
First authorised
01/03/2013
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Amlodipine: supply and approvals

154 authorised products on the HPRA list contain Amlodipine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
1 supply notice, e.g. Perindopril/Amlodipin Denk 4 mg/10 mg Tabletten (16 Jul 2025 to 15 Dec 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 13 years (since 1 March 2013). The HPRA list marks it as marketed in Ireland.

Other medicines with Amlodipine in Ireland

59 other products on the HPRA list contain Amlodipine, from 12 licence holders; 39 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Amlode 10 mg TabletsRowex Limited,National authorisation (PA)Marketed
Amlode 5 mg tabletsRowex Limited,National authorisation (PA)Marketed
Amlodipine Clonmel 10 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Amlodipine Clonmel 5 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Amlodipine Krka 5 mg TabletsKRKA, d.d., Novo mestoNational authorisation (PA)Marketed
Amlodipine Pinewood 10 mg tabletsPinewood Laboratories LtdNational authorisation (PA)Marketed
Amlodipine Pinewood 5 mg TabletsPinewood Laboratories LtdNational authorisation (PA)Marketed
Amlodipine Teva 10 mg TabletsTeva Pharma B.V.National authorisation (PA)Marketed
Amlodipine Teva 5 mg TabletsTeva Pharma B.V.National authorisation (PA)Marketed
Amlodipine/Valsartan Clonmel 10 mg/160 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Amlodipine/Valsartan Clonmel 5 mg/160 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Amlodipine/Valsartan Clonmel 5 mg/80 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed

All 60 products with Amlodipine →

Other substances in ATC group C08CA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group C08CA with this product:

Lercanidipine hydrochloride (8) · Amlodipine besilate (6) · Felodipine (6) · Nimodipine (2)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

KRKA, d.d., Novo mesto holds 362 products on the HPRA list, with 117 different active substances; 189 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.